Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy

This study tests Glanatec (ripasudil eye drops) as a treatment for Fuchs endothelial dystrophy — a condition where the cells lining the inside of the cornea progressively die, causing blurry vision. The treatment works by promoting new cell growth after the diseased layer is removed in a procedure called Descemet stripping. You may be eligible if: - You are between 30 and 91 years old - You have been diagnosed with Fuchs dystrophy grades 2–4 - Your cornea is clear on the edges with sufficient healthy cells - Your best corrected vision in the study eye is 20/40 or worse - You are otherwise a candidate for a corneal transplant - You have an intraocular lens (artificial lens) in the eye from prior cataract surgery You may NOT be eligible if: - You have uncontrolled glaucoma (eye pressure above 25 mmHg) - You have another corneal infection or autoimmune condition - You have advanced swelling of the cornea with haze or blisters - You have a history of herpes eye infection - You have previously had an endothelial corneal transplant in the study eye - You are pregnant or planning to become pregnant within 6 months Talk to your doctor to see if this trial is right for you.